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The literature surrounding psychosexual health and cancer patients
has primarily considered the functional aspects of the disease and its
treatment at the major expense of the emotional sequelae. Sexual
health is deﬁned by WHO as: “a state of physical, emotional, mental,
and social well-being in relation to sexuality; it is not merely the ab-
sence of disease, dysfunction or inﬁrmity. Sexual health requires a pos-
itive and respectful approach to sexuality and sexual relationships, as
well as the possibility of having pleasurable and safe sexual experiences,
free of coercion, discrimination and violence” [1].
A principle goal ofWHO is to assist itsmember states in achieving the
highest attainable standard of health care for all, including sexual and re-
productive health [2]. Global statistics show that the world’s female pop-
ulation is carrying an overwhelming burden of need in this area. Over 200
million women cannot access modern contraception, and millions of
women suffer rape, domestic violence, and sexual abuse, not only in the
context of wars and criminal activities, but also in their own homes [2].
Although the physical sequelae of these disasters can be treated, such
as treatment for sexually transmitted infections, the emotional impact
can frequently be hidden, ignored, or may not reveal its impact until
many years after the event.
Any illness or traumatic life event, past or present, can lead to sexual
problems in the lifetime of a woman, and gynecological cancer is no ex-
ception. It is the root cause or trigger for sexual difﬁculties in at least 50%
of women affected [3]. In 2012, the estimated number of women living
with gynecological cancers was over three million, which means that
potentially 1.5 million gynecological cancer survivors could be affected
by an associated sexual difﬁculty [4].
Within the context of gynecological cancer, many of these problems
can be alleviated if recognized and acknowledged early in the cancer
journey, therefore contributing dramatic improvements to a woman’s
overall well-being.
2. Prevalence of sexual problems in gynecological cancers
It is now estimated that half of the population of either sex will de-
velop cancer at some time in their life. Globally, 40%− 45% of women
will have a sexual problem at some stage, with the prevalence increas-
ing with age [5]. Between 10% and 90% of women with any cancer will
have sexual problems [6] and over 50% of women with gynecological
cancer will have either temporary or persistent sexual difﬁculties [3].
As diagnosis and treatments improve, the number of women survivinghttp://dx.doi.org/10.1016/j.ijgo.2015.06.014
0020-7292/© 2015 Published by Elsevier Ireland Ltd. on behalf of International Federation of
(http://creativecommons.org/licenses/by-nc-nd/4.0/).cancer will increase, and survivorship issues including quality of life
have become increasingly important. Sexuality is a key component of
most subjectivemeasurable quality of life indicators [7]. Sexual function
and enjoyment are important components of survivorship and should
not be ignored.3. What problems are likely to be seen?
Themost common sexual problems can be divided into two groups:
problems of function and/or problems of desire. There is, however, a
complex interplay of organic disorderswith emotional and psychosocial
issues, and these divisions are merely artiﬁcial. Formal deﬁnitions of fe-
male sexual dysfunction have been adopted, including the US classiﬁca-
tions in the Diagnostic and Statistical Manual of Mental Disorders [8],
although having a sexual difﬁculty does not constitute having a mental
health disorder. Basson et al. [9] published a useful classiﬁcation of the
problems. Such classiﬁcations are useful for research purposes, but
may often be less helpful when treating women.
The predominant functional female sexual problem is pain on sexual
intercourse, or dyspareunia. Deep dyspareunia describes intracoital pel-
vic pain, and superﬁcial dyspareunia is pain on vaginal entry. Either
could signify organic disease, and should be appropriately investigated.
If no pathology is demonstrated, and the pain persists, then an emotion-
al cause must be considered and pursued.
Vaginismus, or involuntary spasm of the pubococcygeal and related
musculature, can prevent sexual intercourse taking place. Good history
taking can clarify whether there has been any penetration of the vagina,
not only penile, but by ﬁngers, sex toys, or tampons. If not, this is diag-
nostic of primary vaginismus, and apart from close inspection of the
vulva and offer of gentle digital vaginal examination to determine the
extent of the vaginismus, no further clinical investigation is warranted.
Women with gynecological cancer are more likely to have secondary
vaginismus caused by pain experienced from the disease or its treat-
ment, and fear of the pain occurring during sex [10].
Loss of libido or loss of sexual interest on the other hand is a problem
of desire. There are no physiological markers for loss of desire when its
origins are psychogenic, with psychosocial contributions, past and
present relationships, traumas, and emotional factors all inhibiting the
woman’s wish to be sexual. One of the key ways to determine the ori-
gins of the sexual difﬁculty is to ask about the sexual and emotional re-
lationship between the woman and her partner before the cancer
diagnosis. It should not be assumed that problems are all due to theGynecology and Obstetrics. This is an open access article under the CC BY-NC-ND license
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need to be incorporated into any counselling.
The exception to this is the woman who suddenly becomes meno-
pausal following cancer treatment, who had no problems with sex or
desire prior to her cancer therapy. Appropriate standard therapy for
her menopausal symptoms should be considered; however, the impact
of a cancer diagnosis will be life changing, and drug treatment of hor-
monal deprivation symptoms may not be sufﬁcient without some psy-
chological or counselling support, or may be contraindicated as in the
case of breast and endometrial cancer [11].
4. Sexual difﬁculties arising from symptoms and treatments for
gynecological cancers
A diagnosis of gynecological cancer is overwhelming. While the in-
stinctive professional response from clinicians is to ensure long-term
survival, sexual issues are important for quality of life and should be
considered in the decision-making process [12]. Sexual dysfunction is
one of the most common and distressing consequences of cancer treat-
ment [13]. Many treatments are shown to have sexual impacts, both
positive and negative, and should be discussed fully with the woman
pre-treatment so that she can make an autonomous decision about
her care. Early offer of discussion of sexual issues in the cancer journey
can lead to better sexual outcomes.
4.1. Cervical cancer
Cervical cancer is the most common gynecological cancer world-
wide. Cervical cancer survivors are at risk of sexual pain disorders, no
matter which modality of treatment is used. A small study of patients
who underwent radical vaginal trachelectomy for early stage cervical
cancer showed sexual dysfunction, including loss of libido, for up to
one year following treatment; however, by 12 months, sexual activity
had reached that of healthy women [14]. Following radical hysterecto-
my for locally advanced cervical cancer, there was no signiﬁcant differ-
ence in sexual activity and enjoyment between women with benign or
malignant disease; however, the cancer group hadworse problems than
healthy controls with body image and vaginal functioning [15]. In
women with advanced cervical cancer given chemoradiotherapy, pain
during intercourse was in fact reduced after treatment [16]. This may
have been a result of the resolution of bleeding, discharge, and pelvic
pain. However, the anxiety surrounding cancer remains for many
women. Women surviving up to 15 years following cervical cancer
treatment showed poorer quality of life than healthy controls, and
those who had received radiotherapy were signiﬁcantly more affected
by sexual dysfunction than those who had surgery alone [17]. Despite
this however, orgasm may be unimpaired following radiation [18].
Many additional needswere expressed by womenwith cervical cancer;
however, sexuality and intimacy came to the fore as a predominant
issue for survivorship [19].
4.2. Ovarian cancer
It has been known for some time that the physical and emotional
impact of ovarian cancer can be devastating, leading to sexual as well
as global quality of life issues [20]. One study has shown a prevalence
of 63% for sexual difﬁculties among women with a diagnosis of ovarian
cancer [3]. The effects of chemotherapy and surgery, combinedwith the
anxiety about survival can have a dramatic negative effect on the
woman’s libido, and even women who undertake risk-reducing
salpingo-oophorectomy can suffer sexual dysfunction [21]. Many of
these women are totally unprepared for the devastating effects of sud-
den menopause, with hot ﬂushes, vaginal dryness, and loss of libido re-
placing a previously healthy sex life. This could be helped by more
realistic counselling before the procedure, and increased postoperative
emotional support.4.3. Endometrial cancer
One study has shown that women who had surgery for endometrial
cancer had no differences in their own sexual experience postoperatively,
but compared with healthy controls, they had more sexual difﬁculties
overall [22]. Women with Lynch syndrome who opt for preventive sur-
gery tend to be happy overall with the surgery, but are often unprepared
for the physical adverse effects of menopause [23]. In contrast, Moldovan
et al. [24] has reported that, despite sometimes debilitating menopausal
symptoms, there were no signiﬁcant sexual difﬁculties associated with
the procedure.
4.4. Vulvar cancer
Vulvectomy is a common treatment for vulvar malignancy. This is
increasingly affecting younger women, who are HIV positive. Women
with vulvar cancer can have many years of difﬁculties with sex due to
often distressing vulvar symptoms and bleeding. Following treatment
they still suffer severe dyspareunia and body image distortion due to
the effects of treatment. Although a recent study showed no differences
in psychosocial and sexual functioning before and after vulvectomy, it
was acknowledged that women with vulvar malignancy have a high
risk for sexual problems compared with healthy controls [25]. Factors
associated with postoperative sexual difﬁculties are increased age,
poor overall physical and mental health well-being, and extent of the
surgical excision [25]. This often elderly group of patients is usually
neglected from the psychosexual point of view.
5. Ethnic groups
The majority of the literature related to sexuality and cancer stems
from high-resource countries. Although most of these studies encom-
pass all women, there is a lack of good published evidence on the treat-
ment of the sexual sequelae of cancer in relation to ethnic minority
groups, within a majority culture [26]. Furthermore, data from low-
and middle-income countries are scant. Much of the literature focuses
on sexual distress and activity in relation to HIV and AIDS which, of
course, is a global priority; however, this focus on infection transmission
should not take away from the emotional needs of the womanwho suf-
fers from gynecological cancer. Sexuality research around the globe
must be perceived and researched in terms of cultural, spiritual, ethnic,
and religious contexts.
6. Treatment strategies for sexual problems
6.1. Physical
Sexual problems in women with gynecological cancer may be asso-
ciated with adverse effects of surgical, hormonal, and chemical treat-
ments, as well as by the cancer itself. Fortunately, emotional, sexual,
and quality of life outcomes improve as lessmorbid,moreminimally in-
vasive surgical treatments for gynecological cancers develop [12].
Chemotherapy-induced ovarian failure in cancer patients is associat-
ed with all the possible symptoms of a sudden menopause, combined
with the emotional impact not only of the cancer, but loss of physical
well-being and fertility all at the same time.
Vaginal dryness can be amajor problem to thosewomenwhowish to
have sex [27], and appropriate vaginal moisturizers and lubricants can
help. The issue of vaginal estrogen is still debated, but should be
discussed with the patient, weighing up the risk − beneﬁt ratio for
each individual. Vaginal estrogen will, in most cases, alleviate the dry-
ness, but there may be concerns about using hormones, especially in re-
lation to breast cancer where the evidence is unclear. The scientiﬁc data,
however, support the safety of low dose vaginal estrogen therapy [28]. It
is not well understood that following a few weeks of vaginal estrogen,
the vagina thickens and corniﬁes and estrogen is not absorbed as a result.
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been used in place of vaginal estrogen in women without cancer [29],
and may prove good alternatives in the future [30]. There are non-
hormonal vaginalmoisturizers and lubricants tomake sexual intercourse
more comfortable. Unfortunately, some commercial sexual lubricants
can be hyperosmolar and could cause epithelial disruption, facilitating
HIV transmission [31]. Simple lubricants such as olive oil or liquid glycer-
in have been used successfully in interventions to alleviate pain on inter-
course due to vaginal dryness, combining their use with physiotherapy
and psychosexual counselling.
Treatments with pelvic external beam radiotherapy and/or with
brachytherapymay cause vaginal shortening, tightening, and lack of pli-
ability. The use of vaginal dilators to overcome these complications is
widespread, despite lack of conclusive evidence, either for or against,
either with or without a coating of estrogen cream [32]. Unsurprisingly,
the intrusion of inserting a plastic (or sometimes glass) tube into a ten-
der vagina after treatment is a task that may carry a deep psychological
and emotional impact [33], and will have resultant poor compliance.
Radiation oncologists agree that information about dilator use should
be given before treatment [34], and that sufﬁcient patient information
and support are essential to improve compliance. Sensitivity to emo-
tions and women’s views and personal values in relation to sexuality
are essential supports to encouraging dilator use [35].
6.2. Emotional
Any of the above problems cannot fail to have an emotional impact on
thewoman and onher partner.Many sexual difﬁculties are automatically
blamed on the organic disruption caused by cancer and its treatments;
however, once any clearly indicated treatments have been given, in a siz-
able proportion of cases, the sexual difﬁculty will remain unresolved.
Many sexual difﬁculties are psychogenic, and no amount of skilled
clinical treatments will help if not linked closely to appropriate counsel-
ling, psychological, or psychosexual therapy. This form of intervention
will enable the woman to expose and reﬂect on her sexual difﬁculties,
in the context of her life and relationship not only since the cancer,
but beforehand. This is often a time when past problems, such as child-
hood abuse, or problems with her current partner will surface. Some
partners are disgusted by the physical impacts of cancer, and the rela-
tionship will suffer. On the other hand, some partners become more
supportive and the cancer leads to stronger relationships [36].
6.3. Psychosexual interventions
Classic psychosexual therapy, using brief, focused psychotherapeutic
techniques is the mainstay of treatment. It can be used with an individ-
ual or a couple, of any sexual orientation or cultural or religious back-
ground. This is a way of listening reﬂectively to the patient, so that
they can gain their own insights into their sexual problem. The issue
of genital examination is considered if relevant, as it enables the
woman to connect with her genital area, and may trigger deep-seated
thoughts or anxieties that the woman had blocked emotionally. This,
of course, is a technique used only by clinicians who are qualiﬁed to ex-
amine the patient [37].
Clinical psychologists and counsellors trained in psychosexual work
also treat womenwith sexual problems. Globally, because the availabil-
ity of trained personnel differs,many simple innovative treatment inter-
ventions have been tried. A brief intervention using a well-accepted
treatment, cognitive behavioral therapy (CBT), combined with sexual
health education had positive results on patients who had risk-
reducing salpingo-oophorectomy [21].
Psychosexual interventions work [38], and like all psychodynamic
interventions only require a trained counsellor and ameans of allowing
access to the patient. The internet has enabled access to health care for
many people around the world who are not able to travel long and dif-
ﬁcult land journeys to direct provision of health care. An onlineintervention with a professional moderator has proven acceptable to
gynecological cancer patients with a sexual difﬁculty [39], and another
internet-based sexual difﬁculties interventionwith counselling sessions
proved more successful in improving sexuality issues than without a
counsellor; however, there was no difference between the two groups
in relation to emotional distress and quality of life [40]. Elsewhere, tele-
phone interventions are being used, alsowith some success; however, it
is clear that the knowledge, skills, and training of the health professional
providing the intervention are relevant to the patient outcome.
Multidisciplinary care should form the backbone of treatment of
sexual difﬁculties in women with gynecological cancer, incorporating
physical, psychoeducational, and psychosexual input. Team discussions,
including clinicians, psychosexual therapists, and physiotherapists are
well within the capabilities of many cancer centers, remembering that
the patient and her partner are the focal point and should always
be consulted.
7. Communication
It is impossible to diagnose and treat a sexual problem if one does
not acknowledge that it exists. Many studies in the past have identiﬁed
lack of willingness of doctors and nurses to discuss sex, but sadly recent
research has shown that notmuchhas changed. For instance, in a cohort
sample of 1154 US obstetrician − gynecologists, 60% did not ask pa-
tients about sexual problems [41]. Too often clinicians make value
judgements about their patients including whether sexuality is an im-
portant part of their lives. Such assumptions may include biases about
age, appearance, sexual preferences, and marital status of people who
have sex.
Peoplewith cancer and their partners have unmet sexual information
and support needs [42], often due to the unwillingness of healthcare pro-
fessionals to discuss sexual issues, even though they recognize it may be
important to the patient.
There are many barriers to talking about sex, affecting both the pa-
tient and the clinician, such as cultural background, and age and gender
discrepancies between doctor and patient. Theremay be simple barriers,
such as lack of privacy in a consultation, as often cancer patients are ac-
companied by family or close friends. Patients often state that they feel it
is trivial to take up the doctor’s time with non-life-threatening issues
such as sex.
Clinicians often cite lack of training as a reason that they are un-
comfortable talking about sex and poor provision of this training
has been noted [13]. Different models of communication skills
training have been used and those undertaking the training have
shown greater empathy and were more inclined to use open
questions [43]. This technique of speaking to the patient in an open
rather than interrogative manner can easily facilitate discussion of
intimate issues.
An even greater challenge in communication is the recognition that
individuals are sexual beings up to the end of life. To somewomen in the
palliative phase, sexual touch and closeness to their partner is of vital
importance. Sadly this is rarely recognized and addressed by palliative
care physicians [44].
8. Sexuality
It is important to remember that aminority of the female population
identiﬁes as lesbian, and that about 8% of the population is bisexual.
While this should make no difference to the quality of sexual health
care they receive, lesbians and bisexuals ﬁnd it difﬁcult to disclose
their sexuality to clinicians, often inhibited by their cultural or religious
background, and fears of facing discrimination [45]. If the clinician asks
the patient at the outset if they have a sexual partner, and whether the
partner is male or female, it will greatly enhance the quality of the
doctor − patient interaction. Lesbian partners in particular can be
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portunity to be present if the patient wishes.
9. Training
Despite the recognized need for treatment of sexual problems in
menopause and gynecological cancer, there is poor provision of special-
ist training to ensure that this important area of service provision ismet
[46]. Undergraduate teaching is important, but it is only by recognizing
psychosexual medicine in formal gynecology or oncology training, as a
compulsory requirement of the course, that this situation will begin to
be addressed.
Innovative online programs [47] can make a major impact on global
training opportunities and give trainees around theworld anopportuni-
ty to gain some skills and insight into treating sexual difﬁculties in a
nonjudgmental way.
10. Psychosexual health care is a human right
Owing to the global prevalence of sexual problems associated
with gynecological cancer, it should be within every gynecologist’s
or oncologist’s duty of care to the patient to be aware of and have
some understanding of how to diagnose and facilitate treatment for
sexual problems in a nonjudgmental manner. This is true holistic
medicine, recognizing not only the cancer, but the woman behind
the symptoms, and requires awareness of the emotional, social, and
relationship aspects of the patient’s life. The ability of any person to
enjoy a sexual life free of coercion, shame, disease, or pain in a con-
sensual manner is a fundamental element of the human rights of
women, and should be an unequivocally accepted as part of her gy-
necological cancer care.
Tomake a difference, even in the absence of expensive and sophisti-
cated cancer treatments, just acknowledging, listening, and offering
support to the woman with sexual difﬁculties related to cancer will ul-
timately have a major beneﬁt to her quality of life.
Conﬂict of interest
The author has no conﬂict of interest.
References
[1] World Health Organization. Deﬁning sexual health. Website http://www.who.int/
reproductivehealth/topics/sexual_health/sh_deﬁnitions/en/. AccessedMarch 12, 2015.
[2] WorldHealthOrganization. Ensuringhuman rights in theprovisionof contraceptive in-
formation and services. Guidance and recommendations. Geneva: WHO; 2014. http://
apps.who.int/iris/bitstream/10665/102539/1/9789241506748_eng.pdf?ua = 1.
[3] Hopkins TG, Stavraka C, Gabra H, Fallowﬁeld L, Hood C, Blagden S. Sexual activity
and functioning in ovarian cancer survivors: an internet-based evaluation. Climac-
teric 2015;18(1):94–8.
[4] World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality
and prevalenceworldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.
aspx.
[5] Lewis RW, Fugl-Meyer KS, Bosch R, Fugl-Meyer AR, Laumann EO, Lizza E, et al.
Epidemiology/risk factors of sexual dysfunction. J Sex Med 2004;1(1):35–9.
[6] Syrjala KL, Schroeder TC, Abrams JR, Atkins TZ, Brown WS, Sanders JE, et al. Sexual
function measurement and outcomes in cancer survivors and matched controls.
J Sex Res 2000;37(3):213–25.
[7] Perz J, Ussher JM, Gilbert E. Constructions of sex and intimacy after cancer: Q
methodology study of people with cancer, their partners, and health professionals.
BMC Cancer 2013;13:270.
[8] American Psychiatric Association. Diagnostic and Satistical Manual of Mental Disor-
ders. 5th ed. DSM-5. Arlington, VA: APA; 2013.
[9] Basson R, Althof S, Davis S, Fugl-Meyer K, Goldstein I, Leiblum S, et al. Summary of
the recommendations on sexual dysfunctions in women. J Sex Med 2004;1(1):
24–34.
[10] Lahaie MA, Amsel R, Khalife S, Boyer S, Faaborg-Andersen M, Binik YM. Can fear,
pain and muscle tension discriminate vaginismus from dyspareunia/provoked
vestibulodynia? Implications for the new DSM-5 diagnosis of genito-pelvic pain/
penetration disorder. Arch Sex Behav 2015;44(6):1537–50.
[11] Ulrich l. HRT after endometrial cancer–is it safe? Maturitas 2014;79(3):237–8.[12] Carter J, Stabile C, Gunn A, Sonoda Y. The physical consequences of gynecologic can-
cer surgery and their impact on sexual, emotional, and quality of life issues. J Sex
Med 2013;10(Suppl. 1):21–34.
[13] Bober SL, Varela VS. Sexuality in adult cancer survivors: challenges and interven-
tions. J Clin Oncol 2012;30(30):3712–9.
[14] Froeding LP, Ottosen C, Rung-Hansen H, Svane D, Mosgaard BJ, Jensen PT. Sexual
functioning and vaginal changes after radical vaginal trachelectomy in early
stage cervical cancer patients: a longitudinal study. J Sex Med 2014;11(2):
595–604.
[15] Plotti F, SansoneM, Di Donato V, Antonelli E, Altavilla T, Angioli R, et al. Quality of life
and sexual function after type C2/type III radical hysterectomy for locally advanced
cervical cancer: a prospective study. J Sex Med 2011;8(3):894–904.
[16] Ljuca D, Marosevic G. Impact of chemoradiotherapy on vaginal and sexual func-
tion of patients with FIGO IIb cervical cancer. Bosn J Basic Med Sci 2011;11(1):
62–4.
[17] Le Borgne G, Mercier M,Woronoff AS, Guizard AV, Abeilard E, Caravati-Jouvenceaux
A, et al. Quality of life in long-term cancer survivors: a population based study.
Gynecol Oncol 2013;129(1):222–8.
[18] Lammerink EA, de Bock GH, Pras E, Reyners AK, Mourits MJ. Sexual functioning of
cervical cancer survivors: a review with a female perspective. Maturitas 2012;
72(4):296–304.
[19] Maguire R, Kotronoulas G, Simpson M, Paterson C. A systematic review of the sup-
portive care needs of women living with and beyond cervical cancer. Gynecol
Oncol 2015;136(3):478–90.
[20] Stead ML, Fallowﬁeld L, Selby P, Brown JM. Psychosexual function and impact of
gynaecological cancer. Best Pract Res Clin Obstet Gynaecol 2007;21(2):309–20.
[21] Bober SL, Recklitis CJ, Bakan J, Garber JE, Patenaude AF. Addressing sexual dysfunc-
tion after risk reducing salpingo-ooporectomy: effects of a brief, psychosexual inter-
vention. J Sex Med 2015;12(1):189–97.
[22] Aerts L, Enzlin P, Verhaege J, Poppe W, Vergote I, Amant F. Sexual functioning in
women after surgical treatment for endometrial cancer: a prospective controlled
study. J Sex Med 2015;12(1):198–209.
[23] Chapman JS, Jacoby V, Chen LM. Managing symptoms and maximizing quality of life
after preventive intentions for cancer risk reduction. Curr Opin Obstet Gynecol 2015;
27(1):40–4.
[24] Moldovan R, Keating S, Clancy T. The impact of risk-reducing gynaecological surgery
in premenopausal women at high risk of endometrial and ovarian cancer due to
Lynch syndrome. Fam Cancer 2015;14(1):51–60.
[25] Aerts L, Enzlin P, Verhaeghe J, Vergote I, Amant F. Psychologic, relational, and sexual
functioning in women after surgical treatment of vulvar malignancy: a prospective
controlled study. Int J Gynecol Cancer 2014;24(2):372–80.
[26] Brotto LA, Yule M, Breckon E. Psychological interventions for the sexual sequelae of
cancer: a review of the literature. J Cancer Surviv 2010;4(4):346–60.
[27] Carter J, Stabile C, Seidel B, Baser RE, Gunn AR, Chi S, et al. Baseline characteristics
and concerns of female cancer patients/survivors seeking treatment at a Female
Sexual Medicine Program. Support Care Cancer 2015;23(8):2255–65.
[28] Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and
timing on plasma estradiol levels. Climacteric 2015;18(2):121–34.
[29] De Gregorio MW, Zerbe RL, Wurz GT. Ospemiﬁne: a ﬁrst-in- class, non-hormonal
selective estrogen receptor modulator approved for the treatment of dyspareunia
associated with vulvar and vaginal atrophy. Steroids 2014;90:82–93.
[30] Kingsberg SA, Woodard T. Female sexual dysfunction: focus on low desire. Obstet
Gynecol 2015;125(2):477–86.
[31] Cunha AR, Machado RM, Palmeira-de-Oliveira A, Martinez-de Oliveira J, das Neves J,
Palmeira-de Oliviera R. Characterization of commercially available vaginal lubricants:
a safety perspective. Pharmaceutics 2014;6(3):530–42.
[32] Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy.
Cochrane Database Syst Rev 2014;9:CD007291.
[33] Cullen K, Fergus K, Dasgupta T, Fitch M, Doyle C, Adams L. From ‘sex toy’ to intrusive
imposition: a qualitative examination of women’s experiences with vaginal dilator
use following treatment for gynecological cancer. J Sex Med 2012;9(4):1162–73.
[34] Bakker RM, Vermeer WM, Creutzberg CL, Mens JW, Nout RA, Ter Kuile MM. Qualita-
tive accounts of patients’ determinants of vaginal dilator use after pelvic radiother-
apy. J Sex Med 2015;12(3):764–73.
[35] Cullen K, Fergus K, DasGupta T, Kong I, Fitch M, Doyle C, et al. Toward clinical care
guidelines for supporting rehabilitative vaginal dilator use with women recovering
from cervical cancer. Support Care Cancer 2013;21(7):1911–7.
[36] Maree JE, Mosalo A, Wright SC. “It depends on how the relationship was before you
became ill”. black South African women’s experiences of life partner support
through the trajectory of cervical cancer. Eur J Cancer Care 2013;22(4):459–67.
[37] Skrine R, Montford H. Psychosexual Medicine: an Introduction. 2nd ed. London:
Arnold; 2001.
[38] Bergeron S, Likes WM, Steben M. Psychosexual aspects of vulvovaginal pain. Best
Pract Res Clin Obstet Gynaecol 2014;28(7):991–9.
[39] Classen CC, Chivers ML, Urowitz S, Barbera L, Wiljer D, O’Rinn S, et al. Psychosexual
distress in women with gynecologic cancer: a feasibility study of an online support
group. Psychooncology 2013;22(4):930–5.
[40] Schover LR, Yuan Y, Fellman BM, Odensky E, Lewis PE, Martinetti P. Efﬁcacy trial of
an Internet-based intervention for cancer-related female sexual dysfunction. J Natl
Compr Canc Netw 2013;11(11):1389–97.
[41] Sobecki JN, Curlin FA, Rasinski KA, Lindau ST. What we don’t talk about when we
don’t talk about sex: results of a national survey of US obstetrician/gynecologists.
J Sex Med 2012;9(5):1285–94.
[42] Gilbert E, Perz J, Ussher JM. Talking about sex with health professionals: the
experience of people with cancer and their partners. Eur J Cancer Care July 10
2014 [Epub ahead of print].
S163S.V. Carr / International Journal of Gynecology and Obstetrics 131 (2015) S159–S163[43] Moore PM, Rivera Mercado S, Grez Artigues M, Lawrie TA. Communication skills
training for healthcare professionals working with people who have cancer.
Cochrane Database Syst Rev 2013;3:CD003751.
[44] Sargant NN, Smallwood N, Finlay F. Sexual history taking: a dying skill? J Palliat Med
2014;17(7):829–31.
[45] Formby E. Lesbian and bisexual women’s human rights, sexual rights and sexual
citizenship: negotiating sexual health in England. Cult Health Sex 2011;13(10):
1165–79.[46] Gleser H. Sex, women and the menopause: Are specialist trainee doctors up for
it? A survey of views and attitudes of specialist trainee doctors in Community
Sexual & Reproductive Health and Obstetrics & Gynaecology around sexuality
and sexual healthcare in the (peri)menopause. Post Reprod Health 2015;
21(1):26–33.
[47] Yates P; for Cancer Australia. The psychosexual care of women affected by
gynaecological cancers. A learning resource for health care professionals. http://
modules.cancerlearning.gov.au/psgc/.
